Federico Piacentini

List of Publications by Year
in descending order

57	1,748	430874	276875
papers	citations	18 h-index	41 g-index

58	58	58	2729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. Journal of Clinical Oncology, 2012, 30, 1989-1995.	1.6	330
2	Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. Annals of Oncology, 2013, 24, 101-108.	1.2	145
3	Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. Oncologist, 2008, 13, 838-844.	3.7	133
4	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Annals of Oncology, 2016, 27, 1867-1873.	1.2	109
5	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	10.7	108
6	Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Annals of Oncology, 2013, 24, 2990-2994.	1.2	96
7	Achievements and unmet needs in the management of advanced ovarian cancer. Gynecologic Oncology, 2010, 117, 152-158.	1.4	78
8	A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Annals of Oncology, 2009, 20, 1193-1198.	1.2	70
9	Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Research, 2018, 20, 62.	5.0	54
10	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Management and Research, 2018, Volume 10, 91-103.	1.9	53
11	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	10.7	52
12	Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treatment Reviews, 2010, 36, S62-S66.	7.7	49
13	Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative, Operable Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1050-1057.	1.6	46
14	Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial). Clinical Breast Cancer, 2008, 8, 192-194.	2.4	29
15	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	4.1	25
16	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. Pharmacogenomics Journal, 2016, 16, 472-477.	2.0	22
17	The Role of Exosomes in Breast Cancer Diagnosis. Biomedicines, 2021, 9, 312.	3.2	20
18	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European Journal of Cancer, 2021, 153, 133-141.	2.8	20

#	Article	IF	Citations
19	Phase II, randomized trial of preoperative epirubicin-paclitaxelÂ+/â˜Âgefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Research and Treatment, 2008, 110, 127-134.	2.5	19
20	Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica, 2008, 93, 1252-1255.	3.5	19
21	Prognostic Factors for Breast Cancer: an Immunomorphological Update. Pathology and Oncology Research, 2016, 22, 449-452.	1.9	17
22	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2â˜Âbreast cancer: results from two prospective trials. Breast Cancer Research and Treatment, 2017, 163, 295-302.	2.5	17
23	Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy . Cancer Management and Research, 2019, Volume 11, 9563-9569.	1.9	17
24	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. Clinical Cancer Research, 2020, 26, 5843-5851.	7.0	17
25	Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage IIâ€“III Breast Cancer. Annals of Surgical Oncology, 2011, 18, 2150-2157.	1.5	16
26	Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). Clinical Breast Cancer, 2008, 8, 97-100.	2.4	15
27	Preoperative Carboplatinâ€“Paclitaxelâ€“Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. Annals of Surgical Oncology, 2015, 22, 2881-2887.	1.5	14
28	Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. Journal of Clinical Pathology, 2012, 65, 503-506.	2.0	13
29	Timing for starting second-line therapy in recurrent ovarian cancer. Expert Review of Anticancer Therapy, 2011, 11, 49-55.	2.4	11
30	Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. American Journal of Case Reports, 2017, 18, 208-211.	0.8	11
31	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. Oncotarget, 2018, 9, 31606-31619.	1.8	11
32	Tumor Stroma Manipulation By MSC. Current Drug Targets, 2016, 17, 1111-1126.	2.1	11
33	Primary pulmonary cancer colliding with metastatic breast carcinoma: Hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. Lung Cancer, 2011, 74, 145-148.	2.0	10
34	Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. International Journal of Biological Markers, 2010, 25, 104-111.	1.8	9
35	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International, 2018, 2018, 1-8.	1.9	9
36	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer, 2021, 7, 12.	5.2	9

#	Article	IF	Citations
37	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals, 2021, 14, 43.	3.8	8
38	Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. Anticancer Research, 2014, 34, 3657-62.	1.1	8
39	Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency. Cancers, 2022, 14, 662.	3.7	7
40	Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. International Journal of Biological Markers, 2010, 25, 104-11.	1.8	7
41	Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. Breast Cancer, 2019, 26, 520-523.	2.9	6
42	The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. Journal of Clinical Medicine, 2021, 10, 1705.	2.4	6
43	Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers, 2021, 13, 4894.	3.7	6
44	Abstract PD1-1: Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study. , 2015, , .		6
45	Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 7079.	4.1	4
46	Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. Clinical Breast Cancer, 2022, 22, 289-299.	2.4	3
47	Abstract P2-08-03: Survival analysis of the prospective randomized Cher-Lob study: Correlation with tumor infiltrating lymphocytes. , 2016, , .		2
48	Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. Annals of Oncology, 2016, 27, iv69.	1.2	1
49	Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer. Breast Cancer Research, 2007, 9, .	5.0	0
50	Change in triple-receptor status between primary and recurrent breast cancer: prognostic impact. Breast, 2011, 20, S23.	2.2	0
51	Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. Annals of Oncology, 2016, 27, iv73.	1.2	0
52	Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. Annals of Oncology, 2016, 27, iv75.	1.2	0
53	Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. Annals of Oncology, 2016, 27, vi84.	1.2	0
54	Abstract P3-10-30: Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy. , 2010, , .		0

#	Article	IF	Citations
55	P1-12-18: Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts.. , 2011, , .		0
56	Progress in the Treatment of Early and Advanced Breast Cancer. , 2008, , 239-256.		0
57	Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience. Future Oncology, 2022, 18, 2651-2659.	2.4	0